Optimizing tumor immune response through combination of radiation and immunotherapy

被引:16
作者
El Chediak, Alissar [1 ]
Shamseddine, Ali [1 ]
Bodgi, Larry [2 ]
Obeid, Jean-Pierre [3 ]
Geara, Fady [2 ]
Zeidan, Youssef H. [2 ]
机构
[1] Amer Univ Beirut, Div Hematol Oncol, Dept Internal Med, Data Management & Clin Res Unit,NKBCI,Med Ctr, POB 11-0236, Riad El Solh, Lebanon
[2] Amer Univ Beirut, Dept Radiat Oncol, Med Ctr, Beirut, Lebanon
[3] Beth Israel Deaconess Med Ctr, Dept Internal Med, Boston, MA 02215 USA
关键词
Radiation; Abscopal; Immunotherapy; SBRT; RESISTANT PROSTATE-CANCER; MELANOMA BRAIN METASTASES; CTLA-4; BLOCKADE; LOCAL RADIATION; STEREOTACTIC RADIOSURGERY; CHECKPOINT BLOCKADE; IONIZING-RADIATION; CLINICAL-RESPONSE; PD-1; RADIOTHERAPY;
D O I
10.1007/s12032-017-1025-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiation therapy and immunotherapy are two highly evolving modalities for the treatment of solid tumors. Immunotherapeutic drugs can either stimulate the immune system via immunogenic pathways or target co-inhibitory checkpoints. An augmented tumor cell recognition by host immune cells can be achieved post-irradiation, as irradiated tissues can release chemical signals which are sensed by the immune system resulting in its activation. Different strategies combining both treatment modalities were tested in order to achieve a better therapeutic response and longer tumor control. Both regimens act synergistically to one another with complimentary mechanisms. In this review, we explore the scientific basis behind such a combination, starting initially with a brief historical overview behind utilizing radiation and immunotherapies for solid tumors, followed by the different types of these two modalities, and the biological concept behind their synergistic effect. We also shed light on the common side effects and toxicities associated with radiation and immunotherapy. Finally, we discuss previous clinical trials tackling this multimodality combination and highlight future ongoing research.
引用
收藏
页数:13
相关论文
共 113 条
  • [1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
    Abdel-Wahab, Noha
    Shah, Mohsin
    Suarez-Almazor, Maria E.
    [J]. PLOS ONE, 2016, 11 (07):
  • [2] Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
    Ahmed, K. A.
    Stallworth, D. G.
    Kim, Y.
    Johnstone, P. A. S.
    Harrison, L. B.
    Caudell, J. J.
    Yu, H. H. M.
    Etame, A. B.
    Weber, J. S.
    Gibney, G. T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (03) : 434 - 441
  • [3] Cancer immunotherapies, their safety and toxicity
    Alatrash, Gheath
    Jakher, Haroon
    Stafford, Patricia D.
    Mittendorf, Elizabeth A.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) : 631 - 645
  • [4] Immunotherapy and radiation therapy for malignant pleural mesothelioma
    Alley, Evan W.
    Katz, Sharyn I.
    Cengel, Keith A.
    Simone, Charles B., II
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (02) : 212 - 219
  • [5] Aptsiauri N, 2007, ADV EXP MED BIOL, V601, P123
  • [6] Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
    Barker, Christopher A.
    Postow, Michael A.
    Khan, Shaheer A.
    Beal, Kathryn
    Parhar, Preeti K.
    Yamada, Yoshiya
    Lee, Nancy Y.
    Wolchok, Jedd D.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2013, 1 (02) : 92 - 98
  • [7] Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes
    Barker, Christopher A.
    Postow, Michael A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (05): : 986 - 997
  • [8] HUMAN LYMPHOCYTES-B EXPRESS THE P75 COMPONENT OF THE INTERLEUKIN 2-RECEPTOR
    BEGLEY, CG
    BURTON, JD
    TSUDO, M
    BROWNSTEIN, BH
    AMBRUS, JL
    WALDMANN, TA
    [J]. LEUKEMIA RESEARCH, 1990, 14 (03) : 263 - 271
  • [9] Timeline - Radiation oncology: a century of achievements
    Bernier, J
    Hall, EJ
    Giaccia, A
    [J]. NATURE REVIEWS CANCER, 2004, 4 (09) : 737 - U15
  • [10] Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Bernstein, Michael B.
    Krishnan, Sunil
    Hodge, James W.
    Chang, Joe Y.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 516 - 524